Search Results - "SITBON, Olivier"

Selexipag for the Treatment of Pulmonary Arterial Hypertension by Sitbon, Olivier, Channick, Richard, Chin, Kelly M, Frey, Aline, Gaine, Sean, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M, Lang, Irene M, Preiss, Ralph, Rubin, Lewis J, Di Scala, Lilla, Tapson, Victor, Adzerikho, Igor, Liu, Jinming, Moiseeva, Olga, Zeng, Xiaofeng, Simonneau, Gérald, McLaughlin, Vallerie V

“…Among over 1100 patients with pulmonary arterial hypertension who received selexipag, an oral selective IP prostacyclin-receptor agonist, or placebo, the risk…”
Get full text

Current and future treatments of pulmonary arterial hypertension by Sommer, Natascha, Ghofrani, Hossein A., Pak, Oleg, Bonnet, Sebastien, Provencher, Steve, Sitbon, Olivier, Rosenkranz, Stephan, Hoeper, Marius M., Kiely, David G.

“…Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the…”
Get full text

Treatment of Pulmonary Arterial Hypertension by Humbert, Marc, Sitbon, Olivier, Simonneau, Gérald

“…Pulmonary arterial hypertension, which is characterized by vascular proliferation and remodeling of small pulmonary vessels, leads to a progressive increase in…”
Get full text

French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension by Brenot, Philippe, Jaïs, Xavier, Taniguchi, Yu, Garcia Alonso, Carlos, Gerardin, Benoit, Mussot, Sacha, Mercier, Olaf, Fabre, Dominique, Parent, Florence, Jevnikar, Mitja, Montani, David, Savale, Laurent, Sitbon, Olivier, Fadel, Elie, Humbert, Marc, Simonneau, Gérald

“…To evaluate safety and efficacy of balloon pulmonary angioplasty (BPA) in a large cohort of patients with chronic thromboembolic pulmonary hypertension…”
Get full text

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension by Gaine, Sean, Chin, Kelly, Coghlan, Gerry, Channick, Richard, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Lang, Irene M, McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J, Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F, Hoeper, Marius M

“…Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with other aetiologies. The…”
Get full text

Beyond a single pathway: combination therapy in pulmonary arterial hypertension by Sitbon, Olivier, Gaine, Sean

“…There is a strong rationale for combining therapies to simultaneously target three of the key pathways implicated in the pathogenesis of pulmonary arterial…”
Get full text

External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry by Boucly, Athénaïs, Weatherald, Jason, Savale, Laurent, de Groote, Pascal, Cottin, Vincent, Prévot, Grégoire, Chaouat, Ari, Picard, François, Horeau-Langlard, Delphine, Bourdin, Arnaud, Jutant, Etienne-Marie, Beurnier, Antoine, Jevnikar, Mitja, Jaïs, Xavier, Simonneau, Gérald, Montani, David, Sitbon, Olivier, Humbert, Marc

“…Introduction Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of…”
Get full text

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study by Weatherald, Jason, Chaumais, Marie-Camille, Savale, Laurent, Jaïs, Xavier, Seferian, Andrei, Canuet, Matthieu, Bouvaist, Hélène, Magro, Pascal, Bergeron, Anne, Guignabert, Christophe, Sitbon, Olivier, Simonneau, Gérald, Humbert, Marc, Montani, David

“…This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart…”
Get full text

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience by Sitbon, Olivier, Vonk Noordegraaf, Anton

“…Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial hypertension (PAH). In the 20 years since the introduction of this…”
Get full text

Criteria for diagnosis of exercise pulmonary hypertension by Herve, Philippe, Lau, Edmund M, Sitbon, Olivier, Savale, Laurent, Montani, David, Godinas, Laurent, Lador, Frederic, Jaïs, Xavier, Parent, Florence, Günther, Sven, Humbert, Marc, Simonneau, Gerald, Chemla, Denis

“…The previous definition of exercise pulmonary hypertension (PH) with a mean pulmonary artery pressure (mPAP) >30 mmHg was abandoned because healthy individuals…”
Get full text

Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension by Weatherald, Jason, Boucly, Athénaïs, Chemla, Denis, Savale, Laurent, Peng, Mingkai, Jevnikar, Mitja, Jaïs, Xavier, Taniguchi, Yu, O’Connell, Caroline, Parent, Florence, Sattler, Caroline, Hervé, Philippe, Simonneau, Gérald, Montani, David, Humbert, Marc, Adir, Yochai, Sitbon, Olivier

“…BACKGROUND:Hemodynamic variables such as cardiac index and right atrial pressure have consistently been associated with survival in pulmonary arterial…”
Get full text

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension by Boucly, Athénaïs, Cottin, Vincent, Nunes, Hilario, Jaïs, Xavier, Tazi, Abdelatif, Prévôt, Grégoire, Reynaud-Gaubert, Martine, Dromer, Claire, Viacroze, Catherine, Horeau-Langlard, Delphine, Pison, Christophe, Bergot, Emmanuel, Traclet, Julie, Weatherald, Jason, Simonneau, Gérald, Valeyre, Dominique, Montani, David, Humbert, Marc, Sitbon, Olivier, Savale, Laurent

“…Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated pulmonary…”
Get full text

Pulmonary veno-occlusive disease by Montani, David, Lau, Edmund M, Dorfmüller, Peter, Girerd, Barbara, Jaïs, Xavier, Savale, Laurent, Perros, Frederic, Nossent, Esther, Garcia, Gilles, Parent, Florence, Fadel, Elie, Soubrier, Florent, Sitbon, Olivier, Simonneau, Gérald, Humbert, Marc

“…Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH) characterised by preferential remodelling of the pulmonary venules. In…”
Get full text

Clinical trial design and new therapies for pulmonary arterial hypertension by Sitbon, Olivier, Gomberg-Maitland, Mardi, Granton, John, Lewis, Michael I, Mathai, Stephen C, Rainisio, Maurizio, Stockbridge, Norman L, Wilkins, Martin R, Zamanian, Roham T, Rubin, Lewis J

“…Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on case reports and small series, and was largely ineffectual. As a deeper…”
Get full text

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension by Pulido, Tomás, Adzerikho, Igor, Channick, Richard N, Delcroix, Marion, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Jansa, Pavel, Jing, Zhi-Cheng, Le Brun, Franck-Olivier, Mehta, Sanjay, Mittelholzer, Camilla M, Perchenet, Loïc, Sastry, B.K.S, Sitbon, Olivier, Souza, Rogério, Torbicki, Adam, Zeng, Xiaofeng, Rubin, Lewis J, Simonneau, Gérald

“…In an event-driven trial, macitentan (an endothelin-receptor antagonist) at a dose of 3 or 10 mg was compared with placebo in patients with symptomatic…”
Get full text

EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension by Eyries, Mélanie, Montani, David, Girerd, Barbara, Perret, Claire, Leroy, Anne, Lonjou, Christine, Chelghoum, Nadjim, Coulet, Florence, Bonnet, Damien, Dorfmüller, Peter, Fadel, Elie, Sitbon, Olivier, Simonneau, Gérald, Tregouët, David-Alexandre, Humbert, Marc, Soubrier, Florent

“…Florent Soubrier and colleagues identify biallelic mutations in EIF2AK4 as a major cause of pulmonary veno-occlusive disease, a rare form of pulmonary…”
Get full text

Pulmonary Arterial Hypertension in Patients Treated by Dasatinib by MONTANI, David, BERGOT, Emmanuel, POUBEAU, Patrice, GIRERD, Barbara, NATALI, Delphine, GUIGNABERT, Christophe, PERROS, Frederic, O'CALLAGHAN, Dermot S, JAÏS, Xavier, TUBERT-BITTER, Pascale, ZALCMAN, Gerard, SITBON, Olivier, GÜNTHER, Sven, SIMONNEAU, Gerald, HUMBERT, Marc, SAVALE, Laurent, BERGERON, Anne, BOURDIN, Arnaud, BOUVAIST, Helene, CANUET, Matthieu, PISON, Christophe, MACRO, Margareth

“…The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in patients…”
Get full text

Management of pulmonary arterial hypertension in patients aged over 65 years by Sitbon, Olivier, Howard, Luke

“…Historically, pulmonary arterial hypertension (PAH) has been considered a disease of young adults, but over the last three decades, the average age at…”
Get full text

Initial dual oral combination therapy in pulmonary arterial hypertension by Sitbon, Olivier, Sattler, Caroline, Bertoletti, Laurent, Savale, Laurent, Cottin, Vincent, Jaïs, Xavier, De Groote, Pascal, Chaouat, Ari, Chabannes, Céline, Bergot, Emmanuel, Bouvaist, Hélène, Dauphin, Claire, Bourdin, Arnaud, Bauer, Fabrice, Montani, David, Humbert, Marc, Simonneau, Gérald

“…Treatment for pulmonary arterial hypertension (PAH) has been underpinned by single-agent therapy to which concomitant drugs are added sequentially when…”
Get full text

Treatment Goals of Pulmonary Hypertension by McLaughlin, Vallerie V., MD, Gaine, Sean Patrick, MD, PhD, Howard, Luke S., DPhil, Leuchte, Hanno H., MD, Mathier, Michael A., MD, Mehta, Sanjay, MD, Palazzini, Massimillano, MD, Park, Myung H., MD, Tapson, Victor F., MD, Sitbon, Olivier, MD, PhD

“…With significant therapeutic advances in the field of pulmonary arterial hypertension, the need to identify clinically relevant treatment goals that correlate…”
Get full text